Average Co-Inventor Count = 7.91
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Boehringer Ingelheim International Gmbh (8 from 1,536 patents)
2. Bayer Healthcare LLC (7 from 780 patents)
3. Bayer Pharmaceuticals Corporation (2 from 70 patents)
4. Mirati Therapepeutics, Inc. (1 from 1 patent)
18 patents:
1. 12139484 - Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease
2. 11787819 - Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
3. 11130754 - Substituted benzamides as RIPK2 inhibitors
4. 10138241 - Substituted benzamides as RIPK2 inhibitors
5. 10131642 - Aldosterone synthase inhibitors
6. RE46886 - Alkoxy pyrazoles as soluble guanylate cyclase activators
7. 9353090 - Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
8. 8906904 - Alkoxy pyrazoles as soluble guanylate cyclase activators
9. 8829185 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
10. 8815857 - Soluble guanylate cyclase activators
11. 8338594 - Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
12. 8143393 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
13. 8138336 - Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
14. 8133995 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
15. 8129379 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis